Latest news in cancer
Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer
The USFDA has approved Durvalumab combined with chemotherapy for treating mismatch repair-deficient primary advanced or recurrent endometrial cancer. This...
Repotrectinib has received accelerated approval from the USFDA for adult and pediatric patients with NTRK gene fusion-positive solid tumors
Repotrectinib has received accelerated approval for treating adult and pediatric patients with NTRK gene fusion-positive solid tumors. This approval, based on...
Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer
May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or...
Imetelstat is approved by FDA for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
May 2024: Imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, has been approved by the Food and Drug Administration for use...
Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma
Lisocabtagene maraleucel, a CAR T-cell therapy, has been approved by the FDA for the treatment of adults with relapsed or refractory mantle cell lymphoma. This...
Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer
May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small...
Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma
The FDA has granted accelerated approval to Lisocabtagene maraleucel for treating follicular lymphoma. This CAR T-cell therapy targets the CD19 antigen on...
Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer
Tisotumab Vedotin-tftv has been approved by the FDA for treating recurrent or metastatic cervical cancer. This antibody-drug conjugate targets tissue factor,...
Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma
Tovorafenib has received accelerated approval from the FDA for treating relapsed or refractory BRAF-altered pediatric low-grade glioma. This approval offers...
Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study
CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause...
Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
Seattle Children's Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body's...
Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.